- News Home
24 April 2014 11:45 am ,
Vol. 344 ,
Major climate data sets have underestimated the rate of global warming in the last 15 years owing largely to poor data...
The tsetse fly is best known as the vector for the trypanosome parasites that cause sleeping sickness and a disease in...
The National Institutes of Health is revising its "two strikes" rule, which allowed researchers only one chance to...
By stabilizing the components of retromers, molecular complexes that act like recycling bins in cells, a recently...
Fossil fuels power modern society by generating heat, but much of that heat is wasted. Semiconductor devices called...
Researchers are gaining insights into what made Supertyphoon Haiyan so powerful and devastating through post-storm...
Millions around the world got a first-hand look at what it was like to be in Tacloban while it was pummeled by...
- 24 April 2014 11:45 am , Vol. 344 , #6182
- About Us
FDA Panel Recommends Anti-HIV Drug for Prevention
17 May 2012 1:59 pm
On 10 May, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) held a marathon debate about whether an anti-HIV drug on the market as a treatment should receive approval as a preventive for uninfected people. For more than 12 hours, the committee heard scientific evidence and impassioned arguments for and against, ultimately recommending that FDA approve the use of the drug Truvada for what's called pre-exposure prophylaxis (PrEP). The decision was not unanimous, and there was a protracted back and forth about how to reduce the possibility that PrEP might cause more harm than good.